Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.67 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | BCR | P11274 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5556429 | 0.88 | MAOB (0.78) | MAOBTAAR1SLC13A5ABL1ABCB1 | |
| Hydrochloric Acid SCHEMBL3841387 | 0.87 | MAOB (0.79) | MAOBTAAR1BACE1 | |
| SCHEMBL9308074 | 0.85 | MAOB (0.73) | MAOBSLC13A5ABL1ABCB1BCR | |
| SCHEMBL4842037 | 0.82 | MAOB (1.00) | MAOBTAAR1 | |
| SCHEMBL1180343 | 0.82 | ABL1 (0.69) | MAOBABL1ABCB1BCR | |
| SCHEMBL13952331 | 0.81 | MAOB (0.68) | MAOBSLC13A5ABL1ABCB1BCR | |
| SCHEMBL1336638 | 0.80 | MAOB (0.67) | MAOBTAAR1ABL1ABCB1BCR | |
| SCHEMBL42400 | 0.80 | TAAR1 (1.00) | MAOBTAAR1 | |
| SCHEMBL10468492 | 0.79 | MAOB (0.66) | MAOBSLC13A5ABL1ABCB1BCR | |
| SCHEMBL20777101 | 0.79 | MAOB (0.66) | MAOBSLC13A5ABL1ABCB1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | MAOB 3127/4885TAAR1 4731/4885SLC13A5 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.